<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-ONC-16009027</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2016-08-15</date_registration>
      <primary_sponsor>Xinqiao Hospital, Third Military Medical University</primary_sponsor>
      <public_title>CART cell bridging allogeneic hematopoietic stem cell transplantation for treatment of refractory / relapsed B cell non Hodgkin's lymphoma: non blind, non controlled, single center clinical trial </public_title>
      <acronym />
      <scientific_title>CART cell bridging allogeneic hematopoietic stem cell transplantation for treatment of refractory / relapsed B cell non Hodgkin's lymphoma: non blind, non controlled, single center clinical trial </scientific_title>
      <Scientific_acronym />
      <date_enrolment>2017-05-10</date_enrolment>
      <type_enrolment />
      <target_size>Case series:22;</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=14000</url>
      <study_type>Observational study</study_type>
      <study_design>Case series</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>CD19 positive expression of refractory / relapsed B cell non Hodgkin's lymphoma</hc_freetext>
      <i_freetext>Case series:CART cells bridging allogeneic hematopoietic stem cell transplantation;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Liu Yao</firstname>
        <middlename />
        <lastname />
        <address>183 Xinqiao Main Street, Shapingba District, Chongqing </address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13228684685</telephone>
        <email>648283926@qq.com</email>
        <affiliation>Center of Hematology, Xinqiao Hospital, Third Military Medical University </affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Liu Yao</firstname>
        <middlename />
        <lastname />
        <address>183 Xinqiao Main Street, Shapingba District, Chongqing </address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13228684685</telephone>
        <email>648283926@qq.com</email>
        <affiliation>Center of Hematology, Xinqiao Hospital, Third Military Medical University </affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Male and female aged under 55 years old; 
2. with CD19 expression positive refractory / relapsed non Hodgkin's lymphoma and no effective treatment modality for selected patients;
3. estimated survival tiem less than 3 months; 
4. ECOGâ‰¤2 scores;
5. No serious systemic organ dysfunction.</inclusion_criteria>
      <agemin />
      <agemax />
      <gender>Both</gender>
      <exclusion_criteria>1) Uncontrolled positive infection, HBV or HCV positive;
2) Patients taked part in other cell immunotherapy trials.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>disease-Free survival of 1 years;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Hematopoietic reconstitution time;ratio of GVHD;Complication of therapy;ratio of relapse;overall survival of 1years;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>The clinical research project of Xinqiao Hospital of Third Military Medical University </source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-07-26</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>